Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PET/CT provides MCL staging information

Morgan R et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 4. doi: 10.1016/j.clml.2018.06.024.

Key clinical point: PET/CT provided accurate staging information on mantle cell lymphoma without the use of bone marrow biopsy.

Major finding: If greater than 38% of the voxels demonstrated an standard uptake value of less than 0.95, there was a sensitivity of 100% and a specificity of 80%.

Study details: A retrospective cohort study of 23 patients with mantle cell leukemia and 5 controls.

Disclosures: There was no external funding for the study and the researchers reported having no financial disclosures.

Read the article.

Citation:

Morgan R et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 4. doi: 10.1016/j.clml.2018.06.024.

This Week's Must Reads

Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30

Phase 2 trial evaluates entospletinib in DLBCL, Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331

Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Must Reads in Mantle Cell Lymphoma

First-line chemo-free MCL combo is durable, Ruan J et al. Blood. 2018 Sep 4. doi: 10.1182/blood-2018-07-859769.

Genetic markers signal poor prognosis in MCL, Obr A et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 23. doi: 10.1016/j.clml.2018.07.282

Promise of SGN-CD70A against NHL eclipsed by adverse events, Phillips T et al. Invest New Drugs. 2018 Aug 22. doi: 10.1007/s10637-018-0655-0.

Rituximab maintenance leads to better MCL outcomes, Vidal L et al. HemaSphere. 2018 Aug;2(4):e136.

Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.